Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited, announced that the Japanese Patent and Trademark Office has issued a Decision to Grant a patent covering certain aspects of its proprietary Cymerus mesenchymal stem cell (MSC) manufacturing technology.
The patent granted on Japanese Patent Application No. 2013-500186 entitled "Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-free Conditions" will provide commercial rights in Japan through to March 16, 2031. This patent covers a proprietary method for deriving MSCs from pluripotent stem cells. Cynata has exclusive rights to this patent and to further patents and patent applications in respect of the Cymerus technology pursuant to a license agreement with the Wisconsin Alumni Research Foundation.
"Having an issued Japanese patent for our Cymerus technology is a critical step in the development and commercialization of CYP-001, our first therapeutic MSC product," said Dr Ross Macdonald, CEO of Cynata. "The issued patent will protect this novel discovery and allow Cynata to further progress its commercial partnering activities in Japan, one of the leading markets for regenerative medicine and stem cells."
